Vanda Pharmaceuticals (VNDA) Reports Q2 Loss Per Share of 1c, Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. UNH
7. CVS
8. SBUX
9. AXP
10. ZETA

Go back to Vanda Pharmaceuticals (VNDA) Reports Q2 Loss Per Share of 1c, Offers Guidance

Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results

July 29, 2015 4:02 PM EDT

WASHINGTON, July 29, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the second quarter ended June 30, 2015.

"We are impressed with U.S. sales performance for both HETLIOZ and Fanapt" said Mihael H. Polymeropoulos M.D., Vanda's President and CEO, "further investments in the commercialization and life cycle management of our products set the stage for the next level of growth for Vanda."  

Financial Highlights

Total net product sales for the second quarter of 2015 increased by 25% over the prior... More